Trastuzumab Deruxtecan for brain metastatic squamous lung carcinoma with immune-related hypophysitis: a case report
Rui Xu1, Jiadi Gan1, Jiarui Zhang1
1Department of Pulmonary and Critical Care Medicine, Institute of Respiratory Health, Center of Precision Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Abstract:
Immunotherapy is an important part of the first-line treatment for lung squamous cell carcinoma (LUSC) in the current guidelines. However, in case when patients experience immunotherapy-related adverse reactions, immunotherapy may be discontinued. Antibody-drug conjugates (ADCs) may be an alternative treatment if the patient harbors actionable mutations. Herein, we present a case of brain metastatic LUSC harboring HER2 mutation who experienced hypophysitis after immunotherapy. This patient benefited from Trastuzumab Deruxtecan (T-DXd) after discontinuing immunotherapy. Therefore, T-DXd may be an alternative treatment option for LUSC patients with HER2 mutation who are unable to continue immunotherapy.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers


